On May 31, 2016, the U.S. Food and Drug Administration (FDA) granted a priority review of the new drug application for telotristat etiprate (Lexicon), and oral drug used to treat carcinoid syndrome. As the priority review status shortens the review process to 6 months from the standard 10 months, the FDA will decide whether to approve telotristat etiprate for commercial use by November 30, 2016.

“The granting of priority review by the FDA underscores the need for improving the lives of the patients and caregivers who live with carcinoid syndrome on a daily basis,” said Lexicon CEO Lonnel Coats.

Lexicon press release.